Tirzepatide, a new diabetes drug administered weekly through injection, helped those with type 2 diabetes meet blood glucose goals 4 to 12 weeks earlier than those receiving conventional diabetic drugs.
The phase 3 SURPASS trials, which were published in 2021, proved that tirzepatide reduces blood sugar and promotes weight reduction better than other type 2 diabetes (T2D) drugs. Now, a new study evaluating the time required to achieve blood glucose goals shows that tirzepatide meets blood sugar control and weight reduction goals quicker than existing diabetes drugs.
The latest analyses of the SURPASS-2 and SURPASS-3 trials, which were presented at 2022’s European Association for the Study of Diabetes (EASD) Annual Meeting in Stockholm, Sweden, discovered that adults treated with various doses of injectable tirzepatide (5, 10, and 15 mg) reached blood glucose targets about four weeks sooner than those treated with injectable semaglutide (1 mg), and between four and 12 weeks sooner than those treated with once-daily insulin (degludec; iDeg), along with diet and exercise and oral glucose-lowering medications.
“Tirzepatide is unique because it mimics two natural insulin-releasing and appetite-suppressing hormones in one injection”, says lead author Dr. Adie Viljoen, a Consultant Metabolic Physician and Chemical Pathologist from the East and North Hertfordshire NHS Trust, UK.“The speed we are seeing in glucose-lowering and weight loss is beyond anything else we have available right now and it may put adults with type 2 diabetes in a better position for preventing long-term complications. But it is important to remember that these medications should be used in addition to diet and exercise.”
T2D is a chronic and progressive disorder in which the body does not produce or use insulin normally, resulting in high blood glucose levels. Despite the availability of several drugs to treat diabetes, only about half of US adults with T2D achieve a target hemoglobin A1c (HbA1c; a measure of blood sugar control) of less than 7%. Higher HbA1c levels are linked to heart disease, stroke, kidney disease (nephropathy), eye disease (retinopathy), and nerve disease (neuropathy).
Tirzepatide is a single molecule that belongs to a new class of diabetes drugs that mimics two hormones, glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), involved in blood sugar control and appetite suppression. It was approved for the treatment of T2D by the US Food and Drug Administration in May 2022.
The SURPASS-2 and SURPASS-3 trials compared different doses of tirzepatide (5, 10, and 15 mg) with a once-weekly injectable semaglutide 1 mg (which is a single hormone, GLP-1 mimic agent) as an add-on therapy to metformin, or long-acting insulin (iDeg), as an add-on therapy to metformin with or without a sodium-glucose cotransporter-2 inhibitor, respectively [3].
On average, participants treated with all doses of tirzepatide lowered their HbA1c more than those treated with semaglutide and iDeg, and a greater proportion achieved an HbA1c of less than 7% (